PAI Pharma Acquires Nivagen to Strengthen US Injectable Manufacturing

PAI Pharma has acquired Nivagen Pharmaceuticals in a strategic move aimed at expanding injectable drug manufacturing and development capabilities in the United States. The transaction is expected to enhance production scale, accelerate product pipelines, and improve supply reliability for complex injectable formulations across regulated markets.

Expansion of Sterile Injectable Capabilities:

The acquisition significantly bolsters PAI Pharma’s presence in sterile injectables by adding Nivagen’s expertise in development, regulatory filings, and commercialization. This integration is designed to support a broader portfolio of hospital-focused and specialty injectable products while improving end-to-end manufacturing control.

Strengthening US-Based Supply Chains:

By bringing Nivagen into its operational fold, PAI Pharma aims to reinforce domestic pharmaceutical manufacturing and reduce dependence on external suppliers. The move aligns with industry-wide efforts to localize critical drug production, address injectable drug shortages, and ensure consistent access to essential medicines in the US market.